ArGEN-X NV has raised an additional €1.8 million from its initial public offering on the Euronext stock exchange in Brussels following the partial exercise of an over-allotment option by one of the underwriters.
Oxford Nanopore Technologies Ltd, which develops gene sequencing technology, said that it has raised £35 million in new funding through a private placement of its ordinary shares. The transaction brings to £180 million the total funds raised since its founding in 2005.
Roche has agreed to acquire Santaris Pharma A/S of Denmark, an RNA-targeted medicine specialist with whom it already has a strategic alliance. The Switzerland-based company will pay $250 upfront in cash for the company, with contingent payments of up to $200 million.
The Switzerland-based life science company Evolva Holding SA has reached an agreement to acquire Prosarix Ltd, a privately-owned biotechnology company in Cambridge UK that works in the area of computer-based drug discovery.
AstraZeneca Plc has announced plans to expand its respiratory franchise by in-licensing rights to a group of marketed and investigational products for asthma and chronic obstructive pulmonary disease (COPD) from Almirall SA of Spain.
AbbVie Inc has won the agreement of Shire Plc’s management to create a newly merged biopharmaceutical company that will be domiciled in the UK and listed on the New York Stock Exchange. The deal was secured on 18 July for a combination of shares and cash valued at £52.48 per share. The total deal value is about £32 billion.
Immunocore Ltd of Oxford, UK has secured another partnership with a major pharmaceutical company relating to the exploitation of its recombinant T cell receptor technology platform – this time with Eli Lilly and Company.
Immatics Biotechnologies GmbH has received €22 million from its venture capital investors – the final tranche in a Series D round that will enable it to complete a Phase 3 trial of a cancer vaccine for renal cell carcinoma, a type of kidney cancer.
The Board of Shire Plc has responded favourably to a revised takeover proposal from AbbVie Inc which values Shire at £53.20 per share, up from £51.15 per share earlier. The board is in detailed discussions with the US company about other terms of the proposed deal.
Salix Pharmaceuticals Inc is the latest company to take advantage of low corporate tax rates in Ireland through its planned merger with the Irish subsidiary of Cosmo Pharmaceuticals SpA of Italy. The transaction is expected to close in the fourth quarter.